Related Experiment Video
Updated: Jun 14, 2026

Intrastriatal Injection of Autologous Blood or Clostridial Collagenase as Murine Models of Intracerebral Hemorrhage
Published on: July 3, 2014
c-Jun N-terminal kinase pathway inhibition in intracerebral hemorrhage
Delphine Michel-Monigadon1, Christophe Bonny, Lorenz Hirt
1Department of Clinical Neuroscience, Neurology Service, Centre Hospitalier Universitaire Vaudois and Lausanne University, Lausanne, Switzerland.
Insights
The JNK inhibitor XG-102 reduced brain swelling and improved neurological function in mice with intracerebral hemorrhage (ICH). This suggests XG-102 could be a rapid treatment for stroke patients.
Area of Science:
- Neuroscience
- Pharmacology
- Cerebrovascular Disease Research
Background:
- The c-Jun N-terminal kinase (JNK) pathway is implicated in brain injury.
- JNK inhibition with XG-102 shows neuroprotection in ischemic stroke models.
- The efficacy of JNK inhibition in intracerebral hemorrhage (ICH) requires investigation.
Purpose of the Study:
- To investigate the therapeutic effect of JNK inhibition by XG-102 in a mouse model of intracerebral hemorrhage (ICH).
Main Methods:
- Intracerebral hemorrhage (ICH) was induced in mice via collagenase injection.
- Animals received intravenous injections of XG-102 (100 microg/kg) three hours post-ICH.
- Neurological outcomes were assessed daily, with sacrifice at 6 hours, 1, 2, or 5 days post-ICH.
Main Results:
- XG-102 significantly improved neurological outcomes by day 1 (p < 0.01).
- Lesion volume decreased by day 2 (29 +/- 11 vs. 39 +/- 5 mm(3); p < 0.05).
- Hemispheric swelling was reduced (14 +/- 13 vs. 26 +/- 9%; p < 0.05), correlating with increased aquaporin 4 expression.
Conclusions:
- XG-102 attenuates cerebral edema and functional deficits in early stages of ICH.
- Beneficial effects in ICH, similar to ischemic stroke, suggest potential for rapid pre-imaging treatment in stroke patients.
Background:
Inhibition of the c-Jun N-terminal kinase (JNK) pathway by the TAT-coupled peptide XG-102 (formerly D- JNKI1) induces strong neuroprotection in ischemic stroke in rodents. We investigated the effect of JNK inhibition in intracerebral hemorrhage (ICH).
Methods:
Three hours after induction of ICH by intrastriatal collagenase injection in mice, the animals received an intravenous injection of 100 microg/kg of XG-102. The neurological outcome was assessed daily and the mice were sacrificed at 6 h, 1, 2 or 5 days after ICH.
Results:
XG-102 administration significantly improved the neurological outcome at 1 day (p < 0.01). The lesion volume was significantly decreased after 2 days (29 +/- 11 vs. 39 +/- 5 mm(3) in vehicle-treated animals, p < 0.05). There was also a decreased hemispheric swelling (14 +/- 13 vs. 26 +/- 9% in vehicle-treated animals, p < 0.05) correlating with increased aquaporin 4 expression.
Conclusions:
XG-102 attenuates cerebral edema in ICH and functional impairment at early time points. The beneficial effects observed with XG-102 in ICH, as well as in ischemic stroke, open the possibility to rapidly treat stroke patients before imaging, thereby saving precious time.
Related Concept Videos
Hemorrhagic Stroke ll: Pathophysiology
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Cerebral Edema ll: Pathophysiology
